| Project/Area Number |
24591403
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATO Junji 札幌医科大学, 医学部, 教授 (20244345)
KOBUNE Masayoshi 札幌医科大学, 医学部, 准教授 (90336389)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
|
|---|
| Keywords | AML / fucose / DDS / 白血病 / 細胞標的療法 / 急性骨髄性白血病 / ナノキャリア / フコース |
|---|
| Outline of Final Research Achievements |
Acute myelogenous leukemia (AML) will achieve complete remission by induction therapy due to improvements in supportive and optimization therapy. In order to improve treatment efficacy by anti cancer drugs, specificity of drugs to leukemic cells should be important to ameliorate prognosis, since maximum dose of chemotherapeutic agents might be administered to AML patients, expecting less toxicity and more efficacy. We targeted AML cells utilizing fucose-bound liposome, since we found AML cells actively uptake L-fucose. Herein we report that intravenously injected L-fucose-bound liposomes containing daunorubicin can be successfully delivered to AML cells. This resulted in efficient tumor growth inhibition as well as prolonged survival in tumor-bearing mice. Thus, biological targeting utilizing characteristics of AML cells by fucose-bound liposome could be a promising new strategy for AML treatment.
|
